Haleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain r…
Drug Manufacturers - Specialty & Generic
GB, Weybridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Haleon plc's gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | - | 0.370 | - | 13,154 | - | 3,426 | - | 2,588 | - | 2,211 | - | 5,418 |
| 2023 | - | 0.353 | - | 14,251 | - | 3,270 | - | 2,804 | - | 2,395 | - | 5,870 |
| 2024 | - | 0.361 | - | 14,501 | - | 3,342 | - | 2,853 | - | 2,437 | - | 5,973 |
| 2025 | - | 0.393 | - | 14,828 | - | 3,639 | - | 2,917 | - | 2,492 | - | 6,108 |
| 2026 | - | 0.428 | - | 15,553 | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | 0.477 | - | 16,337 | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | 0.475 | - | 16,588 | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
Overweight
Prev. Grade
n/a
Nov. 6, 2024
Overweight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-16.062% $1.55 · MISS
Nov. 6, 2024Price Then
$9.77
Price Target
$11.20
Price Now
$9.65